164 related articles for article (PubMed ID: 19193989)
1. Structure of the ligand-binding domain of the EphB2 receptor at 2 A resolution.
Goldgur Y; Paavilainen S; Nikolov D; Himanen JP
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2009 Feb; 65(Pt 2):71-4. PubMed ID: 19193989
[TBL] [Abstract][Full Text] [Related]
2. The Ephb2 Receptor Uses Homotypic, Head-to-Tail Interactions within Its Ectodomain as an Autoinhibitory Control Mechanism.
Xu Y; Robev D; Saha N; Wang B; Dalva MB; Xu K; Himanen JP; Nikolov DB
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638814
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition.
Chrencik JE; Brooun A; Recht MI; Nicola G; Davis LK; Abagyan R; Widmer H; Pasquale EB; Kuhn P
J Biol Chem; 2007 Dec; 282(50):36505-13. PubMed ID: 17897949
[TBL] [Abstract][Full Text] [Related]
4. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling.
Himanen JP; Chumley MJ; Lackmann M; Li C; Barton WA; Jeffrey PD; Vearing C; Geleick D; Feldheim DA; Boyd AW; Henkemeyer M; Nikolov DB
Nat Neurosci; 2004 May; 7(5):501-9. PubMed ID: 15107857
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of an Eph receptor-ephrin complex.
Himanen JP; Rajashankar KR; Lackmann M; Cowan CA; Henkemeyer M; Nikolov DB
Nature; 2001 Dec 20-27; 414(6866):933-8. PubMed ID: 11780069
[TBL] [Abstract][Full Text] [Related]
6. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity.
Koolpe M; Burgess R; Dail M; Pasquale EB
J Biol Chem; 2005 Apr; 280(17):17301-11. PubMed ID: 15722342
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2.
Himanen JP; Henkemeyer M; Nikolov DB
Nature; 1998 Dec; 396(6710):486-91. PubMed ID: 9853759
[TBL] [Abstract][Full Text] [Related]
8. The Value of EphB2 Receptor and Cognate Ephrin Ligands in Prognostic and Predictive Assessments of Human Breast Cancer.
Ebrahim AS; Hailat Z; Bandyopadhyay S; Neill D; Kandouz M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360867
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the human ephrin-A5 ectodomain.
Nikolov D; Li C; Lackmann M; Jeffrey P; Himanen J
Protein Sci; 2007 May; 16(5):996-1000. PubMed ID: 17400922
[TBL] [Abstract][Full Text] [Related]
10. The Shb scaffold binds the Nck adaptor protein, p120 RasGAP, and Chimaerins and thereby facilitates heterotypic cell segregation by the receptor EphB2.
Wagner MJ; Hsiung MS; Gish GD; Bagshaw RD; Doodnauth SA; Soliman MA; Jørgensen C; Tucholska M; Rottapel R
J Biol Chem; 2020 Mar; 295(12):3932-3944. PubMed ID: 32060095
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor.
Qin H; Shi J; Noberini R; Pasquale EB; Song J
J Biol Chem; 2008 Oct; 283(43):29473-84. PubMed ID: 18708347
[TBL] [Abstract][Full Text] [Related]
12. NMR structure and dynamics of human ephrin-B2 ectodomain: the functionally critical C-D and G-H loops are highly dynamic in solution.
Ran X; Qin H; Liu J; Fan JS; Shi J; Song J
Proteins; 2008 Aug; 72(3):1019-29. PubMed ID: 18300229
[TBL] [Abstract][Full Text] [Related]
13. Unique structure and dynamics of the EphA5 ligand binding domain mediate its binding specificity as revealed by X-ray crystallography, NMR and MD simulations.
Huan X; Shi J; Lim L; Mitra S; Zhu W; Qin H; Pasquale EB; Song J
PLoS One; 2013; 8(9):e74040. PubMed ID: 24086308
[TBL] [Abstract][Full Text] [Related]
14. Enhanced EphB2-Specific Peptide Inhibitors through Stabilization of Polyproline II Helical Structure.
Tennett JC; Epstein SR; Sawyer N
ACS Chem Biol; 2024 Jun; 19(6):1214-1221. PubMed ID: 38739742
[TBL] [Abstract][Full Text] [Related]
15. The first identification of complete Eph-ephrin signalling in ctenophores and sponges reveals a role for neofunctionalization in the emergence of signalling domains.
Krishnan A; Degnan BM; Degnan SM
BMC Evol Biol; 2019 Apr; 19(1):96. PubMed ID: 31023220
[TBL] [Abstract][Full Text] [Related]
16. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth.
Chaudhari A; Mahfouz M; Fialho AM; Yamada T; Granja AT; Zhu Y; Hashimoto W; Schlarb-Ridley B; Cho W; Das Gupta TK; Chakrabarty AM
Biochemistry; 2007 Feb; 46(7):1799-810. PubMed ID: 17249693
[TBL] [Abstract][Full Text] [Related]
17. Kinetic analysis of the binding of monomeric and dimeric ephrins to Eph receptors: correlation to function in a growth cone collapse assay.
Pabbisetty KB; Yue X; Li C; Himanen JP; Zhou R; Nikolov DB; Hu L
Protein Sci; 2007 Mar; 16(3):355-61. PubMed ID: 17322526
[TBL] [Abstract][Full Text] [Related]
18. Eph/ephrin reverse signalling induces axonal retraction through RhoA/ROCK pathway.
Takeuchi S; Katoh H; Negishi M
J Biochem; 2015 Sep; 158(3):245-52. PubMed ID: 25922200
[TBL] [Abstract][Full Text] [Related]
19. Ectodomain structures of Eph receptors.
Himanen JP
Semin Cell Dev Biol; 2012 Feb; 23(1):35-42. PubMed ID: 22044883
[TBL] [Abstract][Full Text] [Related]
20. Sizes of interface residues account for cross-class binding affinity patterns in Eph receptor-ephrin families.
Guo FY; Lesk AM
Proteins; 2014 Mar; 82(3):349-53. PubMed ID: 24105818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
